331 related articles for article (PubMed ID: 17251918)
1. Myelodysplastic syndromes: the complexity of stem-cell diseases.
Corey SJ; Minden MD; Barber DL; Kantarjian H; Wang JC; Schimmer AD
Nat Rev Cancer; 2007 Feb; 7(2):118-29. PubMed ID: 17251918
[TBL] [Abstract][Full Text] [Related]
2. Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.
Czibere A; Prall WC; Zerbini LF; Jäger M; Kobbe G; Knipp S; Libermann TA; Haas R; Aivado M
Br J Haematol; 2006 Nov; 135(3):355-7. PubMed ID: 16978222
[TBL] [Abstract][Full Text] [Related]
3. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
Singh ZN; Huo D; Anastasi J; Smith SM; Karrison T; Le Beau MM; Larson RA; Vardiman JW
Am J Clin Pathol; 2007 Feb; 127(2):197-205. PubMed ID: 17210514
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions.
Span LF; Rutten E; Gemmink A; Boezeman JB; Raymakers RA; de Witte T
Leuk Res; 2007 Dec; 31(12):1659-67. PubMed ID: 17659774
[TBL] [Abstract][Full Text] [Related]
7. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
9. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndrome in children and adolescents.
Niemeyer CM; Baumann I
Semin Hematol; 2008 Jan; 45(1):60-70. PubMed ID: 18179970
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic strategies for myelodysplastic syndrome.
Barrett J; Battiwalla M
Curr Hematol Rep; 2003 May; 2(3):193-201. PubMed ID: 12901340
[TBL] [Abstract][Full Text] [Related]
12. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
Niemeyer CM; Kratz CP
Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
[TBL] [Abstract][Full Text] [Related]
13. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of myelodysplastic syndromes post-solid organ transplantation: a single institutional experience.
Menes M; Vakiani E; Keller CE; Ho EK; Colovai A; Nichols G; Diuguid D; Mears JG; Murty VV; Alobeid B; Bhagat G
Leuk Res; 2007 Jan; 31(1):59-65. PubMed ID: 16787662
[TBL] [Abstract][Full Text] [Related]
15. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary study of biological characteristics of myelodysplastic syndromes clonal cells].
Li X; Wu LY; Ying SX; Chang CK; He Q; Song LQ; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):478-83. PubMed ID: 18072633
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.
Bruserud Ø; Reikvam H
Expert Opin Ther Targets; 2010 Nov; 14(11):1139-42. PubMed ID: 20942744
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: more prevalent than we know.
Sandhu SK; Sekeres MA
Geriatrics; 2008 Nov; 63(11):10-7. PubMed ID: 18998762
[TBL] [Abstract][Full Text] [Related]
20. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?
Hake CR; Graubert TA; Fenske TS
Bone Marrow Transplant; 2007 Jan; 39(2):59-70. PubMed ID: 17143301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
